Prova Education: Changing the Practice of Medicine - Prova Education

Changing the Practice of Medicine

Changing the Practice of Medicine

Discover CME, tools, and guideline-focused education to
improve your knowledge - and patient outcomes.

Popular

Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
CME/CE Broadcast Replay
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Maria Fleseriu, MD, FACE; Beverly MK Biller, MD, FACP
1.50 credits
- Maria Fleseriu, MD, FACE
- Beverly MK Biller, MD, FACP
- Mark Gurnell, MD
1.50 credits
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
MinuteCE®
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
MinuteCE®
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
NEW EPISODE
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
The Power of Timing: Therapies That Change Outcomes
The Power of Timing: Therapies That Change Outcomes
MinuteCE®
The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
In-Person & Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
MinuteCE®
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD
- Javier Cortes, MD, PhD
0.75 program credits

CME/CE

CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Multiple dates available
1.00 credit
MinuteCE®
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 credits 4 episodes
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 credits 4 episodes
NEW EPISODE
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 program credits
NEW EPISODE
Precision in Practice—Bringing Targeted Therapy to mHSPC
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
MinuteCE®
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD
0.75 program credits
- Tiffany Traina, MD
0.75 program credits

Clinical Practice

What’s Next for TROP2-Directed ADCs in TNBC?
What’s Next for TROP2-Directed ADCs in TNBC?
MinuteCE®
What’s Next for TROP2-Directed ADCs in TNBC?
Tiffany Traina, MD
0.75 program credits
- Tiffany Traina, MD
0.75 program credits
MinuteCE®
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Tiffany Traina, MD; Javier Cortes, MD, PhD
0.75 credits 6 episodes
- Tiffany Traina, MD
- Javier Cortes, MD, PhD
0.75 credits 6 episodes
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH; Robert Coleman, MD, FACOG
1.00 credit
- Susana Campos, MD, MPH
- Robert Coleman, MD, FACOG
- Debra Richardson, MD
1.00 credit
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
CME/CE
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
CME/CE
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits

Programs

Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
CME/CE Broadcast Replay
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
Linda Stein Gold, MD; Lakshi Aldredge, MSN, ANP-BC
1.00 credit
- Linda Stein Gold, MD
- Lakshi Aldredge, MSN, ANP-BC
- Najat M. Watch, PA
1.00 credit
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
MinuteCE®
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Tiffany Traina, MD; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD
- Javier Cortes, MD, PhD
0.75 program credits
ADT Intensification: The Evidence You Can’t Afford to Miss
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®
ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Targeting PTEN: Why It Matters
Targeting PTEN: Why It Matters
MinuteCE®
Targeting PTEN: Why It Matters
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Case: Implementing ADT Intensification in mHSPC
Case: Implementing ADT Intensification in mHSPC
MinuteCE®
Case: Implementing ADT Intensification in mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Molecular Profiling in mHSPC: Informing Treatment Selection
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®
Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit